Skip to main content
OpenTrials
Completed

NCT Number: NCT01195805

The Effects of Amiloride and Spironolactone on Renophysiological and Cardiovascular Variables

The investigators wish to study the effect of retaining potassium. The participants have essential hypertension. The test substances are Amiloride, Spironolactone and placebo. The participants will ingest tablets for 28 days before being examined. We will perform a 24 hours urine collection, 24-hours bloodpressure measurement, blood and urine samples and we also examine the patient using a SphygmoCor.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Essential Hypertension Cardiovascular Diseases Hypertension Vascular Diseases

Age range

40 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Departments of medical research and medicine

Holstebro, 7500, Denmark

About this study

Purpose of the study is to examine the effect of amiloride and spironolactone on

  • Renal function (GFR, u-AQP2, u-ENaCβ, u-cAMP, u-PGE2, CH20, FENa, FEK),
  • Pulsewave velocity, augmentation index central bloodpressure,
  • Vasoactive hormones (PRC, AngII, Aldo, AVP, ANP, BNP and Endot), and
  • Ambulatory bloodpressure

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • hypertension,
  • BMI 18,5-30,
  • non-smoker

Exclusion criteria

  • Smoking
  • Not using contraceptives
  • Other illnesses
  • Drug or alcohol abuse

Treatment and study plan

Spironolactone

Drug

1 tablet twice a day for 28 days

Placebo

Other

1 tablet twice a day for 28 days

Amiloride

Drug

1 tablet twice a day for 28 days

Primary outcomes

  1. Bloodpressure

    Time frame: 24-hours and examination

Sponsors and collaborators

Lead sponsor

Regional Hospital Holstebro

Other

Registry information

Official study title

The Effect of Amiloride and Spironolactone on Renovascular and Cardiovascular Variables in Patients With Essential Hypertension in a Doubleblinded, Randomized, Placebo-controlled, Crossover Study.

Acronym: hass

Important dates

Study start
2010
Primary completion
2015
Study completion
2015
First posted
Sep 6, 2010
Registry last updated
Aug 20, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.